RxDoctor Payments Data

Emily Keller, MD

Dermatopathology · Greenwood, INNPI 1790928497

Payments from drug & device makers

$90,772in general payments, 2019–2025

Across 884 payments — averaging $102.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$58K
  • Galderma Laboratories, L.p.$17K
  • Pfizer$5K
  • Novartis$1K
  • Lilly USA, LLC$1K
  • Sun Pharmaceutical Industries Inc.$998
  • plus $6K from 27 others

What the payments were for

  • Consulting fees$7,8509%
  • Speaking & faculty fees$64,61371%
  • Travel & lodging$4,7335%
  • Food & beverage$12,95214%
  • Education$6241%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few dermatopathology providers in Indianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$497,735
Medicare patients
1,713
Services billed
9,356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib21$131,883
Dupixent PenDupilumab18$95,142
Taltz AutoinjectorIxekizumab13$88,356
OtezlaApremilast13$62,976
Fluorouracil51$4,077
Clobetasol Propionate105$3,878
Ketoconazole160$2,304
Doxycycline Hyclate53$1,275
Minocycline Hcl48$1,013
Hydroxychloroquine Sulfate43$929
Triamcinolone Acetonide111$796
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc46$694
ValacyclovirValacyclovir Hcl39$572
Minoxidil52$468
Dutasteride14$453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$936$131,88321 claims
AmgenOtezla$319$62,97613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few dermatopathology providers in Indianaon file to place this against a meaningful peer group, so we don't.

Other dermatopathology in Greenwood

Where these figures come from

Is this you, or does something look wrong? →